In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

New bacterial mRNA vaccine technology shows promise in fighting plague, and could help address the global threat of ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

HHS cancels funding for Moderna's pandemic flu vaccine development in a move viewed by some as an attack on mRNA technology.

New analysis warns that suboptimal clinical trial designs and overreliance on surrogate markers may allow less effective flu ...

The vaccine will offer protection against H5N1 and is projected to be effective against future viral mutations.

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

The H5N1 avian flu is circulating in cows and other mammals. Whether it will make a permanent leap to humans is another ...

H5N1 avian influenza has long been a concerning virus. Since its discovery in 1996 in waterfowl, bird flu has occasionally ...